PubRank

Massimo Galli

Author PubWeight™ 99.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011 2.45
2 Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002 1.97
3 Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood 2012 1.89
4 Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002 1.52
5 Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol 2015 1.45
6 Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012 1.41
7 Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006 1.40
8 Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther 2011 1.30
9 Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 2003 1.26
10 Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011 1.26
11 Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother 2011 1.22
12 Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002 1.17
13 Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010 1.13
14 Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy. J Acquir Immune Defic Syndr 2010 1.12
15 Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol 2012 1.10
16 Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 2006 1.09
17 Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 2010 1.06
18 Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008 1.05
19 Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol 2009 1.03
20 Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect 2012 1.02
21 Origin, evolution, and phylogeography of recent epidemic CHIKV strains. Infect Genet Evol 2012 1.02
22 Prospective observational study of fever in hospitalized returning travelers and migrants from tropical areas, 1997-2001. J Travel Med 2005 1.00
23 Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. Infect Genet Evol 2011 1.00
24 Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol 2005 0.99
25 Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005 0.99
26 Reversible posterior leukoencephalopathy syndrome in 2 HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2008 0.97
27 Description of a "trans-Saharan" strain of human T-lymphotropic virus type 1 in West Africa. J Acquir Immune Defic Syndr 2008 0.94
28 Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012 0.93
29 Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean Basin. PLoS One 2012 0.93
30 The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology 2014 0.92
31 Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol 2011 0.91
32 Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS 2013 0.91
33 Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS 2010 0.91
34 Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One 2013 0.90
35 Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. AIDS 2003 0.90
36 Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases. Proc Natl Acad Sci U S A 2012 0.88
37 Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. Virology 2008 0.88
38 Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res 2011 0.88
39 Rapid molecular evolution of human bocavirus revealed by Bayesian coalescent inference. Infect Genet Evol 2009 0.88
40 Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 2010 0.88
41 Increased CD36 expression on circulating monocytes during HIV infection. J Acquir Immune Defic Syndr 2005 0.87
42 Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr 2013 0.87
43 Risk factors for HIV/AIDS in a low HIV prevalence site of sub-Saharan Africa. Trop Med Int Health 2007 0.86
44 Phylogeographic reconstruction of HIV type 1B in Montenegro and the Balkan region. AIDS Res Hum Retroviruses 2012 0.86
45 Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. AIDS Patient Care STDS 2010 0.86
46 Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 2004 0.86
47 Reconstruction of the evolutionary dynamics of the A(H1N1)pdm09 influenza virus in Italy during the pandemic and post-pandemic phases. PLoS One 2012 0.86
48 Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol 2011 0.86
49 Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. J Antimicrob Chemother 2012 0.86
50 Reconstruction of the epidemic history of hepatitis B virus genotype D in Albania. Infect Genet Evol 2011 0.86
51 Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS 2015 0.85
52 Establishment of an ex vivo model of monocytes-derived macrophages differentiated from peripheral blood mononuclear cells (PBMCs) from HIV-1 transgenic rats. Mol Immunol 2004 0.85
53 Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. AIDS Res Hum Retroviruses 2012 0.85
54 [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2004 0.85
55 ADAMTS 13 genotype and vWF protease activity in an Italian family with TTP. Thromb Haemost 2003 0.85
56 Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors. J Infect Dis 2002 0.84
57 Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J Antimicrob Chemother 2004 0.84
58 High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology 2007 0.84
59 Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients. PLoS One 2011 0.83
60 Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy. PLoS One 2010 0.83
61 Bayesian phylogeography of Crimean-Congo hemorrhagic fever virus in Europe. PLoS One 2013 0.83
62 Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother 2010 0.83
63 The effect of brushing motion on the cyclic fatigue of rotary nickel titanium instruments. Ann Ist Super Sanita 2010 0.83
64 Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother 2012 0.83
65 Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther 2009 0.82
66 High prevalence of human T-lymphotropic virus type 1 (HTLV-1) in immigrant male-to-female transsexual sex workers with HIV-1 infection. J Med Virol 2004 0.82
67 Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. AIDS 2010 0.82
68 Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals. AIDS Res Hum Retroviruses 2011 0.82
69 Reconstruction of the evolutionary dynamics of the hepatitis C virus 1b epidemic in Turkey. Infect Genet Evol 2011 0.82
70 Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2. J Acquir Immune Defic Syndr 2002 0.81
71 Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis? Clin Infect Dis 2013 0.81
72 Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2014 0.81
73 Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau. J Infect 2010 0.81
74 Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting. Antivir Ther 2013 0.80
75 Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: a pilot study. AIDS Res Hum Retroviruses 2010 0.80
76 Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy. Clin Infect Dis 2008 0.80
77 Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. BMC Infect Dis 2012 0.80
78 Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. AIDS Patient Care STDS 2007 0.80
79 Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of human immunodeficiency virus type 1 unique recombinant forms. J Gen Virol 2008 0.79
80 Trends in hospital admissions at a Department for Infectious Diseases in Italy from 1995 to 2011 and implications for health policies. BMC Public Health 2014 0.79
81 Expression of interleukin-15 and interleukin-15Rα in monocytes of HIV type 1-infected patients with different courses of disease progression. AIDS Res Hum Retroviruses 2011 0.79
82 Profile of infective endocarditis observed from 2003 - 2010 in a single center in Italy. BMC Infect Dis 2013 0.79
83 A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients. PLoS One 2013 0.79
84 Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. Infect Genet Evol 2013 0.79
85 Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. Antivir Ther 2004 0.79
86 Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. Am J Gastroenterol 2006 0.78
87 Self-bone graft and simultaneous application of implants in the upper jawbone. (Fit lock technique). Acta Odontol Latinoam 2011 0.78
88 Subtype assignment and phylogenetic analysis of HIV type 1 strains in patients from Swaziland. AIDS Res Hum Retroviruses 2008 0.78
89 Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. J Clin Virol 2004 0.78
90 Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir. J Clin Virol 2007 0.78
91 Controversy concerning role of ultrasonographic lipoatrophy assessments in HIV patients. AIDS 2006 0.78
92 The pavia consensus statement. AIDS 2003 0.78
93 Candidaemia observed at a university hospital in Milan (northern Italy) and review of published studies from 2010 to 2014. Mycopathologia 2014 0.78
94 The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. New Microbiol 2012 0.78
95 Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma? AIDS 2004 0.77
96 Proven intra and interobserver reliability in the echographic assessments of body fat changes related to HIV associated Adipose Redistribution Syndrome (HARS). Curr HIV Res 2008 0.77
97 Hepatitis B virus genotype distribution in HIV-1 coinfected patients. Gastroenterology 2003 0.77
98 New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. Molecules 2009 0.76
99 Delayed-type hypersensitivity skin testing can predict CD4 count increase in HIV patients with poor immunologic response to HAART. J Acquir Immune Defic Syndr 2003 0.76
100 Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. Antivir Ther 2014 0.76
101 Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease. New Microbiol 2014 0.76
102 IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antivir Ther 2004 0.75
103 Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. J Antimicrob Chemother 2013 0.75
104 KSHV reactivation in post-transplant Kaposi sarcoma. Nat Med 2003 0.75
105 Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement. AIDS Patient Care STDS 2002 0.75
106 OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. Liver Int 2014 0.75
107 Alexander the Great and West Nile virus encephalitis. Emerg Infect Dis 2004 0.75
108 Novel genetic association of TNF-α-238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection. Int J Infect Dis 2013 0.75
109 Phylogeny of human T cell lymphotropic virus type 1 in Peru: a high degree of evolutionary relatedness with South African isolates. AIDS Res Hum Retroviruses 2007 0.75
110 Implant stability evaluation by resonance frequency analysis in the fit lock technique. A clinical study. Ann Stomatol (Roma) 2013 0.75
111 Health technology assessment in the HIV setting: the case of monotherapy. New Microbiol 2014 0.75
112 Inferior alveolar nerve laceration after implant site preparation: A case report. Eur J Oral Implantol 2015 0.75
113 Comparability of echographic and tomographic assessments of body fat changes related to the HIV associated adipose redistribution syndrome (HARS) in antiretroviral treated patients. Ultrasound Med Biol 2008 0.75
114 Tuberculous meningitis in a patient with acute human immunodeficiency virus infection. Int J Tuberc Lung Dis 2010 0.75
115 Increased CD36 expression in vertically human immunodeficiency virus-infected children unrelated to antiretroviral therapy. Pediatr Infect Dis J 2005 0.75
116 Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy. J Acquir Immune Defic Syndr 2005 0.75
117 Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology. New Microbiol 2014 0.75
118 Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus. AIDS Res Hum Retroviruses 2013 0.75
119 Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol. AIDS Res Hum Retroviruses 2005 0.75
120 Hepatitis B virus genotype and subgenotype prevalence and distribution in Montenegro. J Med Virol 2015 0.75
121 Use of 3D cartilage scaffolds for the stabilization of implants and bone regeneration with the fit-lock technique. Acta Odontol Latinoam 2013 0.75
122 Comment on: Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2017 0.75
123 OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients. Antivir Ther 2014 0.75
124 Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan Italy. J Acquir Immune Defic Syndr 2017 0.75
125 Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. New Microbiol 2014 0.75
126 Bayesian skyline plot inference of the Toscana virus epidemic: a decline in the effective number of infections over the last 30 years. Infect Genet Evol 2009 0.75
127 Pneumocystis carinii pneumonia after the discontinuation of long-term antiretroviral therapy in an HIV-1-infected pregnant woman. AIDS 2003 0.75
128 Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results. Curr HIV Res 2011 0.75
129 Tubercular gluteus abscesses: a return to the early 20th century or a consequence of new, unprecedented behaviors? Clin Infect Dis 2011 0.75
130 Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. Ther Drug Monit 2015 0.75
131 Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects. J Antimicrob Chemother 2002 0.75
132 Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation: US evaluation. New Microbiol 2010 0.75
133 Fungal endocarditis observed over an 8-year period and a review of the literature. Mycopathologia 2014 0.75
134 Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. AIDS 2004 0.75